Melkersson-Rosenthal syndrome (MRS) is a rare neurological disorder characterized by a triad of symptoms: periodic facial paralysis, cheiloplasty (puffiness of the lips), and glossoplasty (swelling of the tongue). The syndrome can occur at any age, but is most common in young people between the ages of 15 and 40. Severe symptoms can significantly impair the quality of life of patients, as they affect their appearance, ability to speak, and chew. These manifestations can occur spontaneously and vary greatly in intensity and duration from episode to episode.
History of the disease and interesting historical facts
Melkersson-Rosenthal syndrome was first described in 1888 by two independent researchers – Swedish dermatologist Alfred Melkersson and French neurologist Leon Rosenthal. The researchers noted typical clinical manifestations and pointed out their possible neurological origin. Throughout the 20th century, many studies were conducted aimed at studying the pathogenesis and etiology of this syndrome. According to one of the latest publications in the journal Neurology, in 2016, an increase in the number of cases of MRS was recorded among patients with chronic inflammation of the mucous membranes. Such data highlight the need for further study of the relationship between MRS and other systemic diseases.
Epidemiology
According to statistics, the prevalence of Melkersson-Rosenthal syndrome is approximately 0.2-0.5% in the general population. The highest incidence is observed in patients with craniofacial abnormalities or facial nerve disorders. A 2022 study by the JAMA Dermatology group recorded 42 reported cases among 10,000 patients with neurological disorders, indicating a significant vulnerability in this group. It should also be noted that the disease is diagnosed in women 1.5 times more often than in men.
Genetic predisposition to this disease
Modern research shows that Melkersson-Rosenthal syndrome may be associated with abnormalities in certain genes responsible for neuronal function and their interaction with the immune system. Among the genes studied are the following:
- NGC F13A1 – associated with the regulation of blood clotting and inflammation;
- The HLA-DRB1 gene is associated with autoimmune processes in the body;
- Mutations in genes encoding proteins involved in the transmission of neural signals.
These mutations can lead to disruption of the normal functioning of the facial nerve and, consequently, to the specific symptoms of the syndrome.
Risk factors for the development of this disease
Risk factors that contribute to the development of Melkersson-Rosenthal syndrome include:
- Genetic predisposition – the presence of cases of the syndrome in the family history;
- Immune disorders – the presence of autoimmune diseases such as lupus or xerostomia;
- Environmental factors – exposure to toxic chemicals such as heavy metals;
- Infectious diseases - history of previous viral infections, especially those affecting the nervous system.
Diagnosis of this disease
Diagnosis of Melkersson-Rosenthal syndrome involves analysis of the clinical picture and the patient's medical history. The main symptoms may include the following:
- Recurrent attacks of facial paralysis;
- Swelling of the lips and tongue;
- Headaches and migraine-like symptoms.
Laboratory tests may include blood tests for inflammatory markers, as well as electromyography to evaluate facial nerve function. Radiologic tests, such as CT or MRI, may help rule out other neurologic conditions and identify structural changes. Differential diagnosis should include other causes of facial nerve palsy, such as precursors to the herpes simplex virus or benign lesions.
Treatment
Treatment for Melkersson-Rosenthal syndrome aims to reduce symptoms and prevent relapses. It includes:
- Pharmacological treatment – the use of anti-inflammatory and immunomodulatory drugs, such as corticosteroids;
- Physiotherapy – special exercises to restore the function of the facial muscles;
- Surgical treatment – in rare cases, intervention may be required to correct anatomical abnormalities.
List of medications used to treat this disease
Among the main drugs used to treat the syndrome are:
- Prednisolone – to relieve inflammatory processes;
- Paracetamol – to relieve pain;
- Methotrexate – in the presence of concomitant autoimmune diseases.
Disease monitoring
Monitoring of patients with Melkersson-Rosenthal syndrome includes regular neurological checks, monitoring of relapse rates, and assessment of facial muscle function. Prognosis depends on prompt diagnosis and treatment effectiveness, but complications such as long-term facial paralysis or changes in the patient's psychoemotional state may develop.
Age-related features of the disease
The syndrome can manifest itself at different ages, but is most often diagnosed in young people. In early childhood, the disease may be less pronounced, while in older patients, a more severe course with frequent relapses is observed. In addition, in older patients, chronic diseases can aggravate the manifestations of the syndrome and increase the risk of complications.
Questions and Answers
- What is Melkersson-Rosenthal syndrome? SMR is a neurological disorder characterized by facial nerve paralysis and swelling of the lips and tongue.
- What are the main symptoms of the syndrome? The main symptoms include periodic facial paralysis, swelling of the lips and tongue.
- What are the risk factors for developing SMR? Risk factors include genetic predisposition, autoimmune diseases, and exposure to toxic substances.
- How is the syndrome treated? Treatment includes medications to reduce inflammation, physical therapy and, in some cases, surgery.
- What is the likelihood of recurrence of the disease? The likelihood of recurrence varies considerably but requires ongoing monitoring and corrective therapy.
